

<u>Livdelzi</u>

nformatio	n:			
	· · · · · · · · · · · · · · · · · · ·			
ID:				
-				
<u>, </u>				
er Informa	ation:			
lumber:				
nber				
:				
ite, Zip:				
ed Medica	ation			
e:				
ngth				
ntity:				
uency:				
Rx Route of				
Administration:				
Diagnosis and ICD Code:				
a medicatio can be provient of the DN A: Pless. Pharm tions that	on for your ided. Plea completed ease no nacy pri	patient that requires Prior Authorization before benefit coverage or covered se complete the following questions then fax this form to the toll-free number of form, prescription benefit coverage will be determined based on the that supporting clinical documentation is required or authorization reviews can be subject to trial with a tisted within the criteria. The policies are subject to	erage of addit umber listed be the plan's r for ALL P additional change ba	tional elow. rules.
Is the requ	uest an II	NITIAL or CONTINUATION of therapy?		
	ID: te, Zip: Birth: Per Inform Jumber: te, Zip: te, Zip: te, Zip: te, Zip: te, Zip: te Medicate te: ngth ntity: uency: te of tration: is and ICD ent's prescrip a medication can be provered to the DN A: Ple s. Pharm tions that MAR requ Is the requ [] Initial (Initial)	te, Zip: Birth: per Information: lumber: hber te, Zip: ted Medication e: hgth htity: hency: e of tration: is and ICD Code: ent's prescription beneal a medication for your can be provided. Please not help to the completed of	ID: ite, Zip: dumber: her Information: dumber: her Let, Zip: deed Medication eighth intity: due of irration: is and ICD Code: int's prescription benefit requires that we review certain requests for coverage with the pre a medication for your patient that requires Prior Authorization before benefit coverage or coverance be provided. Please complete the following questions then fax this form to the toll-free nuelipt of the Complete of form, prescription benefit coverage will be determined based on DN A: Please note that supporting clinical documentation is required s. Pharmacy prior authorization reviews can be subject to trial with a stions that are not listed within the criteria. The policies are subject to	ID: ite, Zip: Birth: ler Information: lumber: sher Information: lumber: sher Information: sh

If you have any questions, call: 1-888-258-8250

Version 09.2025

2	Is the patient currently receiving the requested medication?	Yes	No
	[If no, skip to question 6.]		
3	Has the patient been receiving medication samples of the requested medication?	Yes	No
	[If yes, skip to question 6.]		
4	Does the patient have a previously approved prior authorization (PA) on file with the current plan?	Yes	No
	[Note: If the patient does NOT have a previously approved PA on file for the requested medication with the current plan, the renewal request will be considered under initial therapy.]		
	[If no, skip to question 6.]		
5	Has the patient been taking the requested medication for AT LEAST 3 months and has experienced a clinically significant benefit from the medication, as documented by the prescriber? ACTION REQUIRED: Submit supporting documentation.	Yes	No
	[Note: Examples of a response to requested medication are improved biochemical markers of primary biliary cholangitis (PBC) (for example, alkaline phosphatase (ALP), bilirubin, gamma-glutamyl transpeptidase (GGT), aspartate aminotransferase (AST), or alanine aminotransferase (ALT) levels).]		
	[No further questions.]		
6	What is the indication?		
	[] Primary Biliary Cholangitis (PBC) (If checked, go to 7)		
	[] Other (If checked, no further questions)		
7	Is the patient 18 years of age or older?	Yes	No
	[If no, no further questions.]		
8	Has documentation been submitted to confirm the patient has primary biliary cholangitis (PBC) as evidenced by: A) Alkaline phosphatase (ALP) is elevated above the upper limit of normal as defined by normal laboratory reference values, B) Positive anti-mitochondrial antibodies or other primary biliary cholangitis-specific autoantibodies, including sp100 or gp210, if antimitochondrial antibodies are negative, OR C) The patient s histologic evidence of PBC from a liver biopsy (for example, non-suppurative inflammation and destruction of interlobular and septal bile ducts)? ACTION REQUIRED: Submit supporting documentation.	Yes	No
L	If you have any	1	1

If you have any questions, call: 1-888-258-8250

	[If no, no further questions.]		
9	Does the provider attest the patient does not have a have a history of hepatic decompensation (for example, ascites, gastroesophageal varices, variceal bleeding, hepatic encephalopathy, and coagulopathy) and currently does not have active decompensation? [If no, no further questions.]	Yes	No
10	Has documentation been submitted with laboratory values obtained within the last 90 days for the following: A) Alkaline phosphatase (ALP) greater than or equal to 1.67 times upper limit of normal (ULN), B) Aspartate aminotransferase (AST) less than or equal to 3 times ULN, C) Alanine Aminotransferase (ALT) less than or equal to 3 times ULN, D) Total bilirubin less than or equal to 2 times ULN, E) Estimated Glomerular Filtration Rate (eGFR) greater than 45 mL/min/1.73m2, F) International Normalized Ratio (INR) less than 1.1 times ULN, and G) Platelet count greater than or equal to 100,000 cells per microliter? ACTION REQUIRED: Submit supporting documentation. [If no, no further questions.]	Yes	No
11	Has documentation been submitted to confirm that the patient has been receiving ursodiol therapy for GREATER THAN OR EQUAL TO 1 year? ACTION REQUIRED: Submit supporting documentation. [If yes, go to question 13.]	Yes	No
12	Has documentation been submitted to confirm that the patient has an inadequate response or contraindication to receiving ursodiol therapy? ACTION REQUIRED: Submit supporting documentation. [If no, no further questions.]	Yes	No
13	Will the requested medication be used in combination with Iqirvo (elafibranor) or Ocaliva (obeticholic acid)? [If yes, no further questions.]	Yes	No
14	Does the patient have complete biliary obstruction? [If yes, no further questions.]		
15	Will the requested medication be given with concomitant Organic Anion Transporter 3 (OAT3) Inhibitors (for example, probenecid) or strong Cytochrome P450 family 2 subfamily C member 9 (CYP2C9) inhibitors (for example, clotrimazole, fluconazole, or gemfibrozil)?	Yes	No

If you have any questions, call: 1-888-258-8250



	[If yes, no further questions.]		
16	Is the requested medication prescribed by or in consultation with a gastroenterologist and/or hepatologist? [If no, no further questions.]	Yes	No
17	Does the prescribed dosing exceed Food and Drug Administration (FDA) approved indication? [Dosing: 10 mg once daily.]	Yes	No

Please document the diagnoses, symptoms, and/or any other information important to this re	view:

SECTION B: Physician Signature

PHYSICIAN SIGNATURE

DATE

FAX COMPLETED FORM TO: 1-833-896-0656

Disclaimer: An authorization is not a guarantee of payment. Member must be eligible at the time services are rendered. Services must be a covered Health Plan Benefit and medically necessary with prior authorization as per Plan policy and procedures.

Confidentiality: The information contained in this transmission is confidential and may be protected under the Health Insurance Portability and Accountability Act of 1996. If you are not the intended recipient any use, distribution, or copying is strictly prohibited. If you have received this facsimile in error, please notify us immediately and destroy this document.

If you have any questions, call: 1-888-258-8250

Version 09.2025